Greenleaf Peter — SEC insider filings
SEC reporting owner CIK 1363683. 23 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2020-08-11 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 5,125 shares, $54,891 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 11 legs across 8 filings — 564,777 shares, $4,328,431 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 38.
- Largest priced transaction: sale of 195,593 shares @ $8.00 ($1,564,744) in Aurinia Pharmaceuticals Inc., filed 2025-03-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | Chief Executive Officer, Director | 10 | 2 legs · 5,125 sh · $54,891 | 6 legs · 562,386 sh · $4,274,062 | 14 |
| Pelthos Therapeutics Inc. (PTHS) | Director | 5 | — | 5 legs · 2,391 sh · $54,369 | 3 |
| BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) | Director | 4 | — | — | 12 |
| ANTARES PHARMA, INC. (ATRS) | Director | 2 | — | — | 8 |
| Altimmune, Inc. (ALT) | Director | 2 | — | — | 1 |
Insider filings — Greenleaf Peter
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 3 | Altimmune, Inc. (ALT) | Holdings only — no transactions reported | EDGAR |
| 2026-11-04 | 4 | Altimmune, Inc. (ALT) | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2026-10-06 | 4 | Pelthos Therapeutics Inc. (PTHS) | Sale (S): 797 @ $21.17 | EDGAR |
| 2026-07-07 | 4 | Pelthos Therapeutics Inc. (PTHS) | Sale (S): 712 @ $26.00 · Sale (S): 85 @ $27.27 | EDGAR |
| 2026-04-06 | 4 | Pelthos Therapeutics Inc. (PTHS) | Sale (S): 420 @ $20.52 · Sale (S): 377 @ $21.36 | EDGAR |
| 2026-04-01 | 4/A | Pelthos Therapeutics Inc. (PTHS) | Grant/award (A): 25,478 @ $0 | EDGAR |
| 2026-03-03 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 196,403 @ $0 · Tax withholding (F): 100,890 @ $14.21 · Grant/award (A): 328,424 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Tax withholding (F): 100,171 @ $14.40 | EDGAR |
| 2026-01-05 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 165,384 @ $0 · Tax withholding (F): 113,169 @ $15.95 | EDGAR |
| 2025-07-07 | 4 | Pelthos Therapeutics Inc. (PTHS) | Grant/award (A): 25,478 (derivative) · Grant/award (A): 77,640 (derivative) | EDGAR |
| 2025-03-04 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 290,728 @ $0 · Grant/award (A): 333,705 @ $0 · Sale (S): 195,593 @ $8 · Sale (S): 164,947 @ $7.92 · Grant/award (A): 443,973 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Sale (S): 126,981 @ $5.60 | EDGAR |
| 2024-02-22 | 4/A | Aurinia Pharmaceuticals Inc. (AUPH) | Sale (S): 33,047 @ $8.78 | EDGAR |
| 2024-02-22 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 661,538 @ $0 | EDGAR |
| 2023-03-06 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 667,407 · Sale (S): 32,750 @ $8.94 | EDGAR |
| 2022-05-26 | 4 | ANTARES PHARMA, INC. (ATRS) | Disposition to issuer (D): 30,220 @ $5.60 · Disposition to issuer (D): 49,425 @ $5.60 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 46,729 (derivative) · Disposition to issuer (D): 58,246 (derivative) · Disposition to issuer (D): 48,542 (derivative) | EDGAR |
| 2022-03-22 | 4 | BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) | Other (J): 105,034 @ $0 · Disposition to issuer (D): 27,746 (derivative) @ $0 · Disposition to issuer (D): 64,164 (derivative) @ $0 · Disposition to issuer (D): 114,347 (derivative) @ $0 | EDGAR |
| 2022-03-04 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 28,300 @ $0 · Sale (S): 9,068 @ $12.01 · Grant/award (A): 312,240 (derivative) @ $0 · Grant/award (A): 534,188 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) | Option exercise (M): 10,246 @ $0 · Grant/award (A): 114,347 (derivative) @ $3.66 · Grant/award (A): 20,492 (derivative) @ $0 · Option exercise (M): 10,246 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) | Option exercise (M): 35,000 @ $0 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | ANTARES PHARMA, INC. (ATRS) | Grant/award (A): 25,452 @ $4.42 · Grant/award (A): 48,542 (derivative) @ $0 | EDGAR |
| 2021-05-12 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Purchase (P): 2,133 @ $10.15 · Purchase (P): 2,992 @ $11.11 | EDGAR |
| 2020-08-11 | 4 | BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) | Option exercise (M): 35,000 @ $0 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1363683 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs